Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View

Dr. Diane Reidy-Lagunes

GI Oncology · Duke University

View

Dr. Tyler Johnson

GI Oncology · Stanford

View

Dr. James Cleary

GI Oncology · Dana-Farber Cancer Institute

View

Dr. Thorvardur Halfdanarson

GI Oncology · Mayo Clinic Rochester

View

Dr. Linette Bosques

GI Oncology · DFCI/MGB

View

Dr. Shikha Jain

GI Oncology · University Illinois

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Saad Usmani

Myeloma · MSK

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    The Role of Metastasectomy in Patients with Liver-Only Metastases from Gastric Adenocarcinoma.

    Sep 30, 2024DOI: 10.1245/s10434-024-16318-1Journal ArticleASO

    Written by: Ioannis A ZiogasOtto N ThielenSumaya Abdul GhaffarElliott J YeeAndrii KhomiakJakob A DurdenSunnie KimRichard D SchulickAna L GleisnerMartin D McCarterBenedetto Mungo

    Find these authors on Roon

    SK
    Dr. Sunnie Kim
    GI Oncology · Children's Hospital Colorado

    Summary

    BACKGROUND: The role of metastasectomy in patients with liver-only metastases from gastric adenocarcinoma remains under investigation. Therefore, we performed a national registry analysis comparing surgical treatment options for patients with gastric adenocarcinoma and liver-only metastases.PATIENTS AND METHODS: In this retrospective National Cancer Database (2010-2019) study, adults (≥ 18 years) with gastric adenocarcinoma and liver-only metastases (no brain, bone, or lung metastases) were included. Patients were stratified into four groups: no surgical treatment, primary tumor resection (PTR), liver metastasectomy, and PTR with liver metastasectomy. Survival was evaluated using the Kaplan-Meier method, log-rank test, and Cox regression.RESULTS: Of 10,977 included patients, 93.6% underwent no surgical treatment, 4.6% PTR alone, 0.8% liver metastasectomy alone, and 1.0% both PTR and liver metastasectomy. The median OS after no surgical treatment was 6.5 months, after PTR alone 10.9 months, after liver metastasectomy alone 9.9 months, and after PTR and liver metastasectomy 18.6 months. In multivariable analysis, when adjusting for age, sex, race/ethnicity, insurance status, Charlson-Deyo score, chemotherapy, and radiation, PTR and liver metastasectomy was associated with superior OS compared with no surgical treatment (HR 2.17, 95% CI 1.76-2.69, p < 0.001), PTR alone (HR 1.42, 95% CI 1.12-1.79, p = 0.003), and liver metastasectomy alone (HR 1.96, 95% CI 1.45-2.64, p < 0.001).CONCLUSIONS: These data suggest that, in highly selected patients with gastric adenocarcinoma and synchronous liver-only metastases and favorable biology, surgical resection might grant a survival advantage.
    SKDr. Sunnie Kim

    Dr. Sunnie Kim

    Hematology & Oncology · Gastrointestinal Oncology
    Children's Hospital Colorado
    sunnie